SpaceX, NASA say Crew-11 astronaut mission is 'go' for launch to ISS on July 31
CAPE CANAVERAL, Fla. — SpaceX's Crew-11 astronaut mission to the International Space Station for NASA is go for launch.
When Crew-11 launches, a SpaceX Falcon 9 rocket will lift off from historic Launch Complex 39A here at NASA's Kennedy Space Center (KSC), sending a crew of four the ISS for a six-month stay. Mission managers with NASA and SpaceX all polled 'go' to proceed to count down towards a 12:09 p.m. ET (1609 GMT) launch attempt of the Crew-11 mission on Thursday (July 31).
"I'm so eager to see this mission launch, but as always, we launch when we're ready. With a little luck, we'll see a launch soon, and we'll also see a crew come home soon," said Ken Bowersox, associate administrator for NASA's Space Operations Mission Directorate, during a prelaunch briefing at KSC today (July 30). "But be patient with us. Let's make sure that the vehicle is ready to go and that our team is really certain before we hit the button."
The four Crew-11 astronauts will dock with the ISS some 39 hours after launch. They will be flying inside SpaceX's Crew Dragon Endeavour spacecraft, flying on its milestone sixth flight. No other Crew Dragon has flown more than four times.
Steve Stich, manager of NASA's Commercial Crew Program, hailed the milestone in today's briefing. "As you know, this is a really important mission for us. It's our sixth flight of Dragon Endeavour. We worked very hard with SpaceX to complete all the reuse activities for this vehicle," Stich said. "We had certified the vehicles — the Dragons — for only five flights. Now we've completed all that work and we're really ready to go."
Crew-11 consists of NASA astronaut Zena Cardman, who will serve as commander on her first trip to space. In a press briefing earlier this month, Cardman stressed how six-month stays on the ISS like the one she will embark on will help prepare NASA to send astronauts much farther into space.
"Understanding how to live and work for long durations — going and staying — is a really interesting challenge, and I'm grateful that we've gotten the chance to do this — to hone our skills on the ISS, so that we can do this for longer durations on the moon," Cardman said.
"The International Space Station, in my perspective, is an absolutely critical stepping stone as we think about going farther afield."
Joining Cardman as mission pilot is veteran NASA astronaut Mike Fincke, making his fourth trip into space. Fincke previously trained to pilot Boeing's troubled Starliner spacecraft on its first operational mission, but was reassigned as delays and issues continue to plague the Starliner program.
Alongside the two NASA astronauts are Kimiya Yui of the Japan Aerospace Exploration Agency (JAXA), making his second trip to the ISS while serving as Crew-11 mission specialist, and Oleg Platonov of Russia's space agency Roscosmos, mission specialist, making his first trip to space.
Crew-11 will dock at 3 a.m. ET (0800 GMT) on Aug. 2 and will overlap with the Crew-10 astronauts for a few days to ensure a smooth handover before Crew-10 makes its way back to Earth for a splashdown in the Pacific Ocean.
If all goes according to plan, the four members of Crew-11 will remain docked at the ISS for roughly six months before the next NASA astronaut rotation relieves them.
The U.S. Space Force has predicted a 90% chance of favorable weather for Crew-11 at launch time.
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
FDA approves SetPoint's neuroimmune modulation device for RA treatment
The US Food and Drug Administration (FDA) has approved SetPoint Medical's implantable neuroimmune modulation device, SetPoint System, to treat moderate-to-severe rheumatoid arthritis (RA) in adults. The system is designed for individuals who are inadequately managed by or intolerant to current RA therapies such as biological and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs). The system is said to activate the body's natural anti-inflammatory and immune-restorative pathways by delivering electrical stimulation to the vagus nerve once a day. The neurostimulation therapy can potentially provide an alternative treatment without immune-compromising risks. The FDA approval was based on the outcomes of the RESET-RA study, a 242-patient double-blind, randomised, sham-controlled trial, which showed the system's efficacy and safety in this patient group. Patients tolerated the device placement procedure and the stimulation therapy well, with a low incidence of related serious adverse events at 1.7%. SetPoint Medical CEO Murthy Simhambhatla said: 'The approval of the SetPoint System, the first-in-class neuroimmune modulation platform, represents a transformative milestone in the management of autoimmune diseases. 'We are committed to improving the health of people living with RA, and look forward to working with providers and payers to make our innovative therapy accessible to their patients. We plan to introduce the SetPoint System in targeted US cities this year, followed by expansion across the country starting in early 2026.' SetPoint Medical is also exploring the use of its neuroimmune modulation platform for other autoimmune diseases such as multiple sclerosis (MS) and Crohn's disease. In March 2024, the company's neuroimmune modulation device secured a breakthrough device designation to treat relapsing-remitting MS. "FDA approves SetPoint's neuroimmune modulation device for RA treatment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
40 minutes ago
- Yahoo
NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer
CALABASAS, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi-phase 2 clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, was featured on Yahoo Finance's Trader Talk with Kenny Polcari in a podcast episode titled 'AI and Biotech Take on Brain Cancer.' As Trader Talk describes it: 'When a biotech startup lands in a major index just months after its IPO, investors take notice. In this episode of Trader Talk, Kenny Polcari speaks with Amir Heshmatpour, executive chairman and president of NeOnc Technologies (Nasdaq: NTHI), about how the company defied a tough market to go public, secure a $50 million partnership in the Middle East, and join the Russell Microcap Index. Heshmatpour explains NeOnc's focus on intranasal drug delivery for brain cancer, the significance of its partnership with USC's medical school, and how global clinical trials are expanding the company's reach. The conversation also includes how AI and quantum computing could transform the biotech industry. It's a rare behind-the-scenes look at how a small-cap biotech is executing on a global stage.' You can tune in to the episode on Apple Podcasts, Spotify, YouTube, or wherever you listen to your podcasts. ABOUT NEONC TECHNOLOGIES HOLDINGS, Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company's NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc's NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions. For more about NeOnc and its pioneering technology, visit Important Cautions Regarding Forward Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'should,' 'intend,' 'expect,' 'plan,' 'budget,' 'forecast,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'continue,' 'evaluating,' or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information. Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated. The 'Risk Factors' section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds. We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations. 'NEO100' and NEO '212' are registered trademarks of NeOnc Technologies Holdings, Inc. Company Contact:info@ Investor Contact:James CarbonaraHayden IR(646)-755-7412James@

Wall Street Journal
43 minutes ago
- Wall Street Journal
Does Artificial Intelligence Belong In Schools?
Regarding 'A Teachers Union's Dangerous Embrace of AI' (op-ed, Aug. 1), I agree with Rebecca Zimmerman's prescription for helping students flourish—focusing on mental health initiatives, cellphone bans during the school day and science-based reading curriculums—all priorities the American Federation of Teachers champions. Where we disagree is over the effect of artificial intelligence in education, specifically Ms. Zimmerman's assertion that AI is 'another fad that will distract teachers.' AI already has an inescapable influence on nearly every part of our lives. I believe, for better or worse, that it will be as transcendent as the printing press.